Paliperidone Palmitate 100 mg eq.

DRUG3 trials

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Janssen Research & Development, LLC, Janssen-Cilag International NV

Conditions

Schizophrenia

Phase 3

Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia

CompletedNCT00590577

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Schizophrenia

Start: 2007-03-31End: 2008-03-31Updated: 2014-06-04

Phase 4

A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

CompletedNCT03713658

Janssen Research & Development, LLCSchizophrenia

Start: 2018-10-18End: 2019-12-02Updated: 2025-04-27

A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings

CompletedNCT04940039

Janssen-Cilag International NVSchizophrenia

Start: 2021-07-22End: 2024-04-16Updated: 2025-04-27

Related Papers

Feasibility study to evaluate capabilities for conducting psychiatric clinical research within the Rwandan mental healthcare system

BMJ Open2023-04-01

Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia.

2014-05-017 citations

Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial.

2011-04-1148 citations